Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024
May 29, 2024 16:01 ET
|
Immunovant Inc.
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and...
Immunovant Awarded U.S. Patent for IMVT-1402
March 12, 2024 07:30 ET
|
Immunovant Inc.
Composition of matter patent issued with coverage until June 2043Patent also includes methods of use and methods of manufacturing claims NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- Immunovant,...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
February 12, 2024 07:00 ET
|
Immunovant Inc.
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two...
Immunovant to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:00 ET
|
Immunovant Inc.
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
December 20, 2023 16:30 ET
|
Immunovant Inc.
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
November 28, 2023 07:00 ET
|
Immunovant Inc.
Results from the 600 mg MAD cohort for IMVT-1402 similar to previously disclosed results from the 300 mg MAD cohort for IMVT-1402IMVT-1402 was observed to deliver dose dependent and deep IgG...
Immunovant to Present at Upcoming Investor Conferences
November 13, 2023 08:00 ET
|
Immunovant Inc.
NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
November 09, 2023 07:00 ET
|
Immunovant Inc.
Positive initial Phase 1 data for IMVT-1402 announced, bolstering best-in-class potentialInitial 600 mg multiple-ascending dose (MAD) cohort data for IMVT-1402 expected in November 2023Initial Phase 2...
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 02, 2023 16:52 ET
|
Immunovant Inc.
NEW YORK, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...
Immunovant Announces Pricing of $450 Million Common Stock Financing
September 27, 2023 23:41 ET
|
Immunovant Inc.
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today...